Daniel J Drucker @DanielJDrucker Twitter profile

Pinned Tweet

Daniel J Drucker

1 month

The efficacy and safety of the new GLP-1 medicines continues to garner interest and will be discussed #ADA2024 Here is an updated safety-focused summary of the field and where it might be headed @DiabetesCareADA #T2D #obesity

3

43

170

Last Seen Profiles

@AbhayKu44661050

@runes_land

@Amoroso58335376

@bntldrb787280

@pengen_stw

@Eu_helitonn

@bntldrb775715

@me_Fara_G

@UrbanAchievrr

@AldrbMwa94487

@bokeplokalmalam

@bntldrb7570651

@BintAldarb56886

@jaxon_sayers

@AldrbBnt35290

@GoddessRosexxxo

@denverfps_

@sirsadoo

@rr_BTS7

@stwmaniax

@OVTeUruFkILFJdm

@NDSUgolf

@lupebargiela

@pengen_stw

@SabrinaM2812

@nGqmiCGYgGconr2

@ronh_pm

@birdman46049238

@stw_pdg

@Couplehot9492

@metatork

@bnt1575579

@Adam910420

@BAlkhbr14179

@TacticuteDilf

@bny1010

Daniel J Drucker

@DanielJDrucker

6 years

2018 accomplishments 1)Most of our knockouts had no meaningful phenotypes 2) When we increased (n) statistical significance usually disappeared 3) Many of my hypotheses flat out wrong 4)Trainees rescued me almost every time 5)Valued truth over hyperbole

11

143

1K

Daniel J Drucker

@DanielJDrucker

3 years

Postdoc position pls R/T-help us figure out gut hormone action-you don't have to be highly motivated, or brilliant-we aren't any of those things either. Curiosity, high ethical standards, thoughtfulness, a flair for generating reproducible (negative) results, that's how we roll

21

216

468

Daniel J Drucker

@DanielJDrucker

24 days

As GLP-1 medicines evolve to target more receptors beyond the GLP-1R, ideally exhibiting enhanced efficacy, new questions arise about long term safety. Mechanistic and outcome studies will help define the value proposition for each NCE in the clinic

3

163

421

Daniel J Drucker

@DanielJDrucker

1 year

Retatrutide, the triple G, Glucagon-GIP-GLP-1 based triagonist produces substantial resolution of liver fat #NAFLD in PPL with #obesity #ADA2023 @ADA_DiabetesPro @AmDiabetesAssn #NASH trial coming

8

112

388

Daniel J Drucker

@DanielJDrucker

3 years

The most effective medical therapy developed to date for #obesity the GLP-1R Agonist Semaglutide 2.4mg once weekly (Wegovy) now approved in the USA @US_FDA @novonordisk

13

131

367

Daniel J Drucker

@DanielJDrucker

4 years

Last week we lost a giant in the world of #diabetes , Roger Unger, a radioimmunoassay pioneer, father of modern glucagon biology, an innovator who shaped our concepts of islet biology #glucagon #T1D #T2D @hypoglycemia @JDRF @UTSWNews @theNASciences @AmDiabetesAssn

14

113

316

Daniel J Drucker

@DanielJDrucker

9 months

Another huge win for GLP-1, semaglutide and PPL with #T2D at risk of developing #kidney disease. FLOW stopped early for efficacy @novonordisk

4

86

291

Daniel J Drucker

@DanielJDrucker

1 year

There are now hundreds of authoritative experts that opine daily on the risk of GLP-1 therapies, often scaring people about the risk #pancreatitis Yet after 18 years in the clinic for #T2D there is no signal for pancreatitis in RCTs or real world data

10

98

280

Daniel J Drucker

@DanielJDrucker

3 years

With GLP-1 as your peptide backbone the world of metabolism beckons. @LillyDiabetes @LillyPad presents new data for 1) Once weekly oxyntomodulin & 2) The triple GLP1R-GCGR-GIPR agonist in people with #T2D Bariatric surgery-like weight loss with GLP-1 medicines is coming #obesity

9

80

281

Daniel J Drucker

@DanielJDrucker

10 months

The gut brain #microbiota axis via the vagus nerve defined via commensal bacterial translocation to the mouse brain and microglial activation in models of diverse neurological diseases

9

73

262

Daniel J Drucker

@DanielJDrucker

4 years

I am priveleged to know and learn from dozens of outstanding female colleagues in cardiology and diabetes, all world experts. Here we have a wonderful meeting, 39 men on the Scientific Committee 0 Women #Manels Lets do better, its 2020 @picardonhealth

17

46

256

Daniel J Drucker

@DanielJDrucker

8 months

The most effective GLP-1-based medicine to date, Tirzepatide, approved by @US_FDA for treatment of people living with #obesity and weight management, marketed as Zepbound, by @EliLillyandCo 2.5-15mg doses, 20% less expensive than 2.4 semaglutide ow

FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option...

The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.

investor.lilly.com

7

79

251

Daniel J Drucker

@DanielJDrucker

2 years

GLP-1-based therapies are slowly approaching #bariatricsurgery level #weightloss and more exciting science to come. There is the impressive SURMOUNT-1 trial for tirzepatide #obesity

Tirzepatide Once Weekly for the Treatment of Obesity | NEJM

Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-li...

www.nejm.org

5

71

242

Daniel J Drucker

@DanielJDrucker

1 year

In 2023 @DiabetologiaJnl @EASDnews will publish a special issue dedicated to the ~40 years of GLP-1 biology. A "how it started, how its going" look at the science with Jens Holst @Metabolcenter #diabetes #obesity #heartdisease #NASH #Alzheimers

2

56

241

Daniel J Drucker

@DanielJDrucker

4 years

Muscles, myokines, and metabolic health. Use it or lose it? igHh intensity or regular #exercise A featured topic #EndocrineReviews #diabetes #obesity #aging #insulin resistance

3

71

243

Daniel J Drucker

@DanielJDrucker

1 year

First oral semaglutide made a strong impression in OASIS-1 #obesity with 15% #weightloss now orforglipron leads the impressive pack of new small molecule oral GLP-1RA with robust #Weightloss and good tolerability ADA2023

3

57

232

Daniel J Drucker

@DanielJDrucker

1 year

Finally, we know how #metformin works, in the gut to increase basolateral intestinal glucose uptake (BIGU) and via gut liver cross talk to reduce hepatic glucose production @PNASNews #diabetes

Metformin acts in the gut and induces gut-liver crosstalk | PNAS

Metformin is the most prescribed drug for DM2, but its site and mechanism of action are still not well established. Here, we investigated the effec...

www.pnas.org

7

96

235

Daniel J Drucker

@DanielJDrucker

10 months

GLP-1 based medicines and the treatment of #obesity How low can one go? @NatureMedicine #weightloss

3

68

233

Daniel J Drucker

@DanielJDrucker

2 years

Just some of the fascinating insights that rocked the GLP-1 incretin world this week-a glimpse of top line data for AMG-133 the GIPR Antagonist-GLP1R Agonist antibody. One dose every 4 weeks for 12 weeks, total of 3 doses, 14.5% #weightloss We never know what we don't know @Amgen

10

56

226

Daniel J Drucker

@DanielJDrucker

9 months

Lots of interest in muscle loss, quality and strength after #weightloss with GLP-1-based therapies. Here Tirzepatide reduces the fat content of muscle, with modest changes in muscle volume #EASD2023 @EASDnews

3

72

228

Daniel J Drucker

@DanielJDrucker

4 months

Here comes once weekly insulin #diabetes

4

72

223

Daniel J Drucker

@DanielJDrucker

1 year

Another GLP-1 win #obesity with more options coming. Oral semaglutide posts >17% #weightloss 15.1% placebo subtracted in OASIS-1

2

69

222

Daniel J Drucker

@DanielJDrucker

3 years

As we recognize collective scientific achievements we must continually re-invest in our students, trainees and new scientists as they establish their own careers. Supporting their success will provide unanticipated novel solutions ensuring the health and prosperity of all nations

Justin Trudeau

@JustinTrudeau

3 years

Congratulations to Canada’s own Dr. @DanielJDrucker and Dr. @EAEisenhauer on this well-deserved recognition. Through your research and your leadership, you represent the very best of our country and make our world a better and healthier place - thank you. #GairdnerAwards

34

65

408

5

30

220

Daniel J Drucker

@DanielJDrucker

15 days

Clinical strategies for mitigating adverse events with GLP-1 medicines @BevTchangMD #ADA2024

3

77

222

Daniel J Drucker

@DanielJDrucker

11 months

The incretin (r)evolution. From discovery to mechanism, clinical utility to access of GLP-1 medicines. The Editors @DiabetologiaJnl summarize the special issue @EASDnews @DiabetologiaJnl @AnnaKrook_KI @hinmul #diabetes #obesity #heartdisease

1

69

208

Daniel J Drucker

@DanielJDrucker

20 days

GLP-1 medicines started with injectable GLP-1RAs, then moved to oral peptides, and now co-agonists. The future will usher in multiple new ways of delivering GLP-1 medicines, and activating GLP-1R signaling pathways, promising improved efficacy/convenience.

0

63

213

Daniel J Drucker

@DanielJDrucker

3 years

New review @MolMetab @jfcryan A comprehensive assessment of the evidence for and against roles for #microbiota and the control of body weight #weightloss #obesity

6

84

207

Daniel J Drucker

@DanielJDrucker

4 years

Random #COVID ー19 musing. Ok, you are smart. However your PhD in nutrition, biochemistry, cancer biology, neuroscience, or your medical expertise in a medical specialty does not make you qualified to opine on a new virus you know nothing about. Bottle the narcissism. Stay silent

4

41

204

Daniel J Drucker

@DanielJDrucker

11 months

The scientific community is thrilled to acknowledge the appointment of Professor Anne-Claude Gingras, a global expert in proteomics and systems biology, as the new Director of the Lunenfeld-Tanenbaum Research Institute @SinaiHealth @uoftmedicine @UofT @gingraslab1 @uoftmedgen

37

20

204

Daniel J Drucker

@DanielJDrucker

1 month

GLP-1 medicines produce adverse events, predominantly gastrointestinal, transient in most. Yet controversy continues surrounding what AEs are rare but real vs. alleged but not rigorously proven in RCTs or real world data. Free to read @DiabetesCareADA

6

73

204

Daniel J Drucker

@DanielJDrucker

3 years

This week, we celebrated my moms 93 birthday. On April 8, Yom Hashoah, we commemorate millions of innocent people slaughtered during World War 2, including my grandmother and aunt, shown here, and dozens of family members who perished. Evil is enabled when you look the other way

7

21

197

Daniel J Drucker

@DanielJDrucker

4 years

Cold shower for the #microbiome crowd. "95% of published studies on HMA rodents reported transfer of pathological phenotypes to recipient animals. We posit that this exceedingly high rate of inter-species transferable pathologies is implausible" Indeed

8

92

193

Daniel J Drucker

@DanielJDrucker

9 months

Neural circuits underpinning control of food intake, energy expenditure, and systemic metabolism-therapeutic implications @ScienceMagazine #obesity #diabetes #weightloss

1

62

191

Daniel J Drucker

@DanielJDrucker

6 years

Metformin discovered in 1922, was introduced as a drug for #diabetes in 1957. Within the last 18 months we have many "definitive" mechanistic studies in mice, rats and humans, acute & chronic dosing, showing how metformin lowers glucose. Yet most of them are largely contradictory

10

75

188

Daniel J Drucker

@DanielJDrucker

11 months

Losing weight vs. sustaining #weightloss Data suggest that weight loss vs. weight loss maintenance are physiologically and psychologically different in many ways @NatMetabolism #obesity

Differential mechanisms affecting weight loss and weight loss maintenance

Nature Metabolism - Rosenbaum and Foster discuss the metabolic underpinnings of weight loss and weight loss maintenance, as well as the implications of considering them as distinct metabolic states...

www.nature.com

2

66

189

Daniel J Drucker

@DanielJDrucker

1 year

Astonishing, did we all not realize that people with hypertension, high cholesterol, inflammatory bowel diseases, all kinds of chronic inflammatory arthritis, CLL, CML, hypothyroidism (I could go on) relapse with discontinuation of medicines? We need to recalibrate our mindsets

Neil Floch MD

@NeilFlochMD

1 year

People taking obesity drugs Ozempic and Wegovy gain weight once they stop medication

10

16

40

7

23

187

Daniel J Drucker

@DanielJDrucker

2 years

Scientists are under pressure to repeatedly produce highly novel data that fundamentally shifts understanding of current concepts. Is this realistic? Does it prompt us to stretch the truth in our relentless search for innovation/novelty? How often are stories too good to be true?

8

40

187

Daniel J Drucker

@DanielJDrucker

1 year

An overview of the new data #obesity #T2D for GLP-1-based medicines, from oral small molecule GLP-1RA, to higher dose oral #Semaglutide to Cagri-Sema and Triple G retatrutide via @NatureNV @saimamaysidik The future is bright

Beyond Ozempic: brand-new obesity drugs will be cheaper and more effective

Nature - Hormone mimics offer advantages even beyond those of the potent weight-loss jabs on the market now.

www.nature.com

8

60

184

Daniel J Drucker

@DanielJDrucker

1 year

The future of gut hormone GLP-1 based pharmacology #T2D #obesity #NASH #heartfailure from the GLP-1 special issue @DiabetologiaJnl @EASDnews @MatthiasTschop

2

64

184

Daniel J Drucker

@DanielJDrucker

6 months

A concise overview of several key publications in the @jclinicalinvest that helped build the story of GLP-1 science @the_asci #Diabetes #T2D #obesity #heartdisease #kidney #Parkinsonsdisease #weightloss #islets

6

59

183

Daniel J Drucker

@DanielJDrucker

11 months

The authors present 74 key genes for #obesity , which are highly interconnected and enriched in several biological processes that contribute to obesity, including energy expenditure and homeostasis. #Genetics

Deciphering the genetic landscape of obesity: a data-driven approach to identifying plausible...

Journal of Human Genetics - Deciphering the genetic landscape of obesity: a data-driven approach to identifying plausible causal genes and therapeutic targets

www.nature.com

3

62

175

Daniel J Drucker

@DanielJDrucker

1 year

As the magnitude of #weightloss achieved w GLP-1-based medicines continues to increase, more attention has shifted to "quality" of weight loss, preservation of lean mass and muscle strength, with consideration of sarcopenic #obesity Yet to date, physical activity improves in most

5

34

171

Daniel J Drucker

@DanielJDrucker

2 years

Free to read this week #EndocrineReviews @EndoSocJournals download the PDF and Figures/slides GLP-1 #MAFLD #NASH

2

47

171

Daniel J Drucker

@DanielJDrucker

2 years

Some news #Tirzepatide #Obesity @US_FDA @LillyPad

1

51

169

Daniel J Drucker

@DanielJDrucker

3 years

“We suggest that although #insulin plays an important role in body fat regulation, the CIM fails because it focuses on the direct action of insulin on adipose tissue after the consumption of a meal containing carbohydrates” @KevinH_PhD @JohnSpeakman4

8

44

170

Daniel J Drucker

@DanielJDrucker

2 years

From #stemcells to #islet biology, mouse physiology to human #genetics the Outstanding Scientist Achievement Awardee @AmDiabetesAssn covers all the bases #ada2022 Congratulations to Professor @annagloyn @Stanford @UniofOxford

5

16

140

Daniel J Drucker

@DanielJDrucker

6 years

Old fashioned physiology, small data, non-automated, often tedious, & rarely sexy, has fallen out of favour, with shiny modern massive OMICs enjoying the limelight. One minor problem. For drug discovery, physiology is essential for target validation, therapeutic efficacy & safety

Terry Maratos-Flier

@Maratosflier

6 years

@DShaywitz @nntaleb Big data does not necessarily provide insight into physiology. Need that for targeting pathways. Think GLP1, SGLT2i. Big data help?

0

6

8

48

165

Daniel J Drucker

@DanielJDrucker

11 months

A very SELECT result. Moving the needle for the medical care #obesity #heartdisease #CVD #Semaglutide Awaiting the details on contributions of 3 MACE components

3

33

160

Daniel J Drucker

@DanielJDrucker

1 year

Animal models of #diabetes @NatureRevEndo

Mammalian models of diabetes mellitus, with a focus on type 2 diabetes mellitus

Nature Reviews Endocrinology - Small rodents are still the most widely used animal model to study the pathophysiology of diabetes mellitus but non-rodent species can also provide valuable insights....

www.nature.com

0

46

165

Daniel J Drucker

@DanielJDrucker

1 year

More evidence for GLP-1 (semaglutide) reducing binge-like and dependence-induced alcohol drinking in mice and rats @JCI_insight

2

29

162

Daniel J Drucker

@DanielJDrucker

2 years

SGLT2 identified as a regulator of cell surface PD-L1 degradation, revealing a potential therapeutic target using SGLt2i to overcome immune evasion by tumor cells @jclinicalinvest

2

53

161

Daniel J Drucker

@DanielJDrucker

10 months

Metabolically Healthy #Obesity Is it a real thing, or a transient stop on the way to more serious disorders? The 2023 Burrow Lecture, Professor Sam Klein, Friday September 29, 8 am live and virtual @uoftmedicine @BBDC_UofT @physiologyuoft

8

46

162

Daniel J Drucker

@DanielJDrucker

2 years

Does the future of medical #weightloss therapies include preferential sparing of lean mass coupled with increased energy expenditure? #obesity

5

46

161

Daniel J Drucker

@DanielJDrucker

9 months

After the most traumatic and deadly day for Jews in a generation, the leaders of most Canadian and international academic institutions, home to tens of thousands of Jewish students and faculty, had absolutely nothing to say. The silence in the face of moral depravity is deafening

7

29

158

Daniel J Drucker

@DanielJDrucker

7 months

The 2023 Breakthrough of the Year. GLP-1 science changes the field of #Obesity meets its match | Science

3

37

155

Daniel J Drucker

@DanielJDrucker

9 months

Symposium 18 #EASD2023 @EASDnews SGLT2 inhibitors and GLP-1 receptor agonist: mechanisms of beneficial action beyond glycaemic control For the figures

1

60

154

Daniel J Drucker

@DanielJDrucker

1 year

Semaglutide first (20 wks) then addition of aerobic exercise (12 wks) in people with #T2D = substantial weight loss (8.9kg) maintenance of lean mass, increased #insulin AUC and C-peptide, improved insulin sensitivity

Effects of Aerobic Training and Semaglutide Treatment on Pancreatic β-Cell Secretory Function in...

AbstractContext. Prior to this study, it is known that type 2 diabetes is linked to obesity and a sedentary lifestyle, leading to inadequate β-cell functio

academic.oup.com

2

42

152

Daniel J Drucker

@DanielJDrucker

6 years

No one chooses their parents or country of birth. My parents endured horrors beyond belief, survived, and traveled across continents in search of a new life in a democratic tolerant country 🇨🇦 welcomed them 65 years ago. Not a day that I am not thankful. Happy Birthday Canada

6

18

154

Daniel J Drucker

@DanielJDrucker

7 months

Newsflash. 99% of all chronic disorders relapse after stopping medical therapy

CNBC

@CNBC

7 months

Patients regain weight after stopping Eli Lilly's Zepbound, study says

20

12

41

5

24

151

Daniel J Drucker

@DanielJDrucker

5 months

#Obesity therapeutics. The GLP-1 based medicines under development. What is coming next? @profmjdavies @IntJObesity @eka_melson @ri_tis

2

52

153

Daniel J Drucker

@DanielJDrucker

16 days

As some of you congregate #ADA2024 that occasional reminder that health and life are precious and should never be taken for granted. Hug your colleagues, kiss your kids, call your parents. Take that vacation. George Bakris and David Wasserman, gone far too soon 💔

4

17

155

Daniel J Drucker

@DanielJDrucker

1 year

The anti- #cancer effects of calorie restriction but not #intermittent fasting are mediated by the gut #microbiota B. bifidum, acetate production & accumulation of interferon-γ+CD8+ T cells in the tumour microenvironment in female mice @NatMetabolism

The antitumour effects of caloric restriction are mediated by the gut microbiome

Nature Metabolism - The authors show that caloric restriction increases the intestinal abundance of Bifidobacterium bifidum, which in turn blunts tumour development in mice.

www.nature.com

1

57

149

Daniel J Drucker

@DanielJDrucker

7 months

The neuroendocrine physiology of appetite and weight regulation with a focus on hypothalamic circuits and #obesity @ucl

0

48

149

Daniel J Drucker

@DanielJDrucker

16 days

The SELECT symposium #ADA2024 cardioprotection with semaglutide does not depend on A1c #obesity @DiabetesCareADA

5

52

150

Daniel J Drucker

@DanielJDrucker

2 years

GLP-1….. who knew? Never touted as very fancy, papers usually eschewed by top Journals for lack of definitive mechanism, yet science published in subspecialty Journals was highly reproducible, from mice to humans, 🇨🇦 to 🇩🇰. Don’t underestimate careful basic and clinical science

Eric Topol

@EricTopol

2 years

I wrote about the new anti-obesity drugs—semaglutide (Wegovy) and tirzepatide (Mounjaro)—that represent one of the most important breakthroughs in medicine

81

521

2K

3

14

148

Daniel J Drucker

@DanielJDrucker

2 years

My late father Ernest, of blessed memory, would have been 100 today. He joined the British army Czech brigade, was wounded in Tobruk, and managed to restart a new life in the fledgling state of Israel. Dad would be shocked to see how #antisemitism remains a scourge amongst us

7

3

146

Daniel J Drucker

@DanielJDrucker

4 years

Based on fascinating animal data “in #T2D the defended level of blood glucose can be restored to normal by therapies that restore the brain’s ability to properly sense the circulating glucose level” @DiabetologiaJnl

2

52

148

Daniel J Drucker

@DanielJDrucker

1 year

Hyponatremia is rarely a good thing. A new review on SIADH #Vasopressin #Hypothalamus #Kidney #EndocrineReviews

0

52

146

Daniel J Drucker

@DanielJDrucker

2 years

GLP-1 and GIP are physiologically essential for suppression of #inflammation and pharmacologically suppress inflammation, actions potentially relevant to reduction of complications #T2D How and where do incretins instruct the immune system?

2

37

145

Daniel J Drucker

@DanielJDrucker

9 months

GLP-1R agonists powerfully suppress gut chylomicron secretion, actions we don’t routinely measure in the clinic with fasting lipids. Does this mechanism contribute to reduction of #atherosclerosis and #MACE #heartdisease @DiabetologiaJnl

1

54

146

Daniel J Drucker

@DanielJDrucker

5 years

Suggestion. Before you launch your press release, think of all the real people and families battling the disease you targeted in your organoids and mice. Many are truly desperate for real progress now, not in 5 years. Now read your press release again, and look hard in the mirror

Cecile Janssens

@cecilejanssens

5 years

"Exaggerated reporting of science runs the risk of creating a perpetual attitude of distrust in science that is harmful to science, researchers and society." "university press releases read like news articles, describing a discovery in engaging language"

18

130

325

0

38

146

Daniel J Drucker

@DanielJDrucker

4 months

A @NobelPrize worthy pursuit. The science of G Protein Coupled Receptors @jclinicalinvest

0

40

146

Daniel J Drucker

@DanielJDrucker

2 years

This week, the debate on time restricted feeding vs. Intermittent fasting vs. Calorie reduction heats up #diets #weightloss #obesity Here is an updated perspective free to read @EndocrineReviews @SatchinPanda

0

47

142

Daniel J Drucker

@DanielJDrucker

1 year

With SURMOUNT-2 results imminent, there will soon be H2H trials of Semaglutide 2.4mg vs. Tirzepatide, and likely Cagri-Sema vs. Tirzepatide #Obesity #T2D @LillyPad @novonordisk

Lilly will test its weight loss drug directly against Novo Nordisk's Wegovy

With tens of billions of dollars on the line and people scrambling to get the drug, Eli Lilly is planning to start testing its weight loss treatment candidate in a head-to-head clinical trial against...

endpts.com

5

33

142

Daniel J Drucker

@DanielJDrucker

3 years

It took almost 4 decades and thousands of dedicated scientists, but GLP-1R agonists are slowly changing the options and improving outcomes for PPL with #T2D #CVD and now #Obesity @juliaoftoronto @seeleyrj @ObesitySociety @ObesityCan via @voxdotcom

A lizard’s venom inspired a promising weight loss drug

Semaglutide is the start of a new chapter in obesity treatments.

www.vox.com

3

36

139

Daniel J Drucker

@DanielJDrucker

5 years

As discussed most of our GLP-1 findings over the years were rejected by "high impact" Journals. This paper describing GLP-1 inhibition of apoptosis is now featured @jbiolchem after 700+ citations. Don't let glam Journals define you

5

27

142

Daniel J Drucker

@DanielJDrucker

1 year

By generating #insulin producing cells from gastric organoids #stemcells the authors provide proof of concept for a promising approach to treat #diabetes @NatureCellBio

Stomach-derived human insulin-secreting organoids restore glucose homeostasis

Nature Cell Biology - Huang et al. provide a method to generate human gastric stem cell-derived pancreatic islet-like organoids that are capable of restoring glucose homeostasis in diabetic mice.

www.nature.com

0

41

142

Daniel J Drucker

@DanielJDrucker

4 years

Among our more popular articles of 2020, #mitochondria play critical roles in every cell, and are central to the pathophysiology of many metabolic disorders encountered in #endocrinology #metabolism #diabetes #obesity #exercise

5

43

140

Daniel J Drucker

@DanielJDrucker

2 years

Congratulations to all the scientists who have worked so hard for decades to understand the autoimmunity of type 1 #Diabetes A new era begins to slow beta cell destruction #islets @ProventionBio @JDRF @T1D_TrialNet

1

43

142

Daniel J Drucker

@DanielJDrucker

7 months

#weightloss in real world databases Tirzepatide vs Semaglutide

4

35

140

Daniel J Drucker

@DanielJDrucker

2 months

The new powerful GLP-1 medicines at doses used for #obesity are relatively new. Yet the class of GLP-1 medicines is now 19 years old, with Exenatide approved for #T2D April 28 2005. We have millions of treatment years for this class. Happy birthday Exenatide/GLP-1 medicines!

5

23

140

Daniel J Drucker

@DanielJDrucker

2 years

The CNS control of metabolism is intricate and fascinating-is the brain a therapeutic target for #diabetes

2

50

139

Daniel J Drucker

@DanielJDrucker

11 months

A new review NAFLFD, MAFLD, MASLD, NAFLD-Ald, ALD, and Met-ALD @NatRevGastroHep

The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease

Nature Reviews Gastroenterology & Hepatology - In this Review, Arrese and colleagues discuss the intersection of nonalcoholic fatty liver disease and alcohol-related liver disease, including...

www.nature.com

0

52

139

Daniel J Drucker

@DanielJDrucker

3 years

Development of novel flourescent glucose sensors for rapid, high-resolution live imaging of glucose influx, efflux, and metabolism in animals @CellReports

In vivo glucose imaging in multiple model organisms with an engineered single-wavelength sensor

Keller et al. describe a glucose-specific single-wavelength genetically encoded fluorescent sensor with a high signal-to-noise ratio and fast kinetics. They use it to follow glucose transport in...

www.cell.com

0

35

138

Daniel J Drucker

@DanielJDrucker

1 year

After decades of gut #microbiota #obesity research➡️A mechanistic linkage between gut commensals and obesity through the overproduction of microbe-derived lipids impairing intestinal epithelial integrity to promote metabolic endotoxemia @Cell_Metabolism

Fatty acid overproduction by gut commensal microbiota exacerbates obesity

The mechanistic linkage between obesity and gut microbiota remains elusive. Takeuchi et al. report that a member of commensal microbiota prevalent in individuals with diabetes and obesity produces...

www.cell.com

0

42

138

Daniel J Drucker

@DanielJDrucker

1 year

The cardiovascular era for GLP-1RA started with preclinical data, then was launched by LEADER in 2016 and 7 subsequent CVOTs. How and where does GLP-1 produce a CV benefit? Some thoughts #CVD #T2D #diabetes #Heartdisease #Atherosclerosis @NatRevCardiol

2

34

139

Daniel J Drucker

@DanielJDrucker

4 years

In 2021 after the cells are all singly sequenced, OMICs fully completed, and circuits fired up and down with opto and chemogenetics, folks will rediscover the forgotten old wizards of systems physiology and ask “So how does this biological system actually work?”

4

21

138

Daniel J Drucker

@DanielJDrucker

2 years

Congratulations to Professor Dale Abel @IntMedAbel @TheEndoSociety @dgsomucla on election to @theNASciences for seminal contributions to metabolism, #diabetes and molecular cardiology

4

14

139

Daniel J Drucker

@DanielJDrucker

1 year

Few journalists write articles describing return of disease symptoms after stopping dozens of different medicines for chronic disorders, cause folks would say “Really? What did you expect?” So why the ‘surprise/fuss about #obesity and #weightloss medicines

Ozempic Can Cause Major Weight Loss. What Happens if You Stop Taking It? (Published 2023)

As more patients turn to diabetes medications for other uses, a shortage has taken hold. But doctors say going off these drugs can take a toll.

www.nytimes.com

12

19

137

Daniel J Drucker

@DanielJDrucker

1 year

18 years ago, I was sitting in a bar in La Jolla with Amylin Pharma colleagues, waiting for the NDA approval for the worlds first GLP-1 receptor agonist, exenatide twice daily, for #T2D Amazingly, the story has expanded in ways few could have imagined. Support #science #research

4

13

135

Daniel J Drucker

@DanielJDrucker

2 years

Bernie Zinman became Professor Emeritus July 1 after 45 years @uoftmedicine @UHN @SinaiHealth @BBDC_UofT @DiabetesCanada @NIDDKgov From YUL to YYZ, NIH to DCCT, EMPAREG-Outcome to LEADER, Bernie has fascinating stories to tell. Think you know Dr. Zinman?

10

15

135

Daniel J Drucker

@DanielJDrucker

2 years

There are many heros of the #COVID19 pandemic that go above and beyond, working tirelessly behind the scenes, without a "look at me" strategy to draw attention @ErinBearss @SinaiHealth @UofTFamilyMed @uoftmedicine is one of those leaders, intrumental in organizing #vaccines 🙏

University of Toronto

@UofT

2 years

Reopened vaccine clinic on #UofT St. George campus set to deliver more than 30,000 doses during latest wave 💙

2

15

94

4

12

134

Daniel J Drucker

@DanielJDrucker

9 months

Notable that so many social justice warriors, including scientists, rushed to insert #BlackLivesMatter or 🇺🇦 flags in your timelines, now have nothing to say publicly as Jews are slaughtered. Please don’t ever again comment about human rights if your morality is so twisted

10

21

132

Daniel J Drucker

@DanielJDrucker

6 months

Happy (80th!) Birthday to Professor Ron Kahn, a pioneer in the molecular mechanisms of #insulin action #diabetes @JoslinDiabetes @harvardmed @theNASciences @AmDiabetesAssn @JDRF @NIDDKgov @diabetesmaster @jclinicalinvest @the_asci

1

6

135

Daniel J Drucker

@DanielJDrucker

4 years

A rabbi, priest, guru and imam meet to resolve the outstanding questions & problems facing the worlds great religions. Remarkably they find good agreement and a unifying path forward. As they are leaving one of them asks "How do you think metformin works?"

1

35

133

Daniel J Drucker

@DanielJDrucker

5 years

Boom. Here comes the latest PIONEER #T2D @US_FDA approves first oral GLP-1 treatment for type 2 #diabetes

FDA approves first oral GLP-1 treatment for type 2 diabetes

FDA approves Rybelsus (semaglutide) oral tablets to improve blood sugar in adults with type 2 diabetes. It is first GLP-1 receptor protein treatment.

www.fda.gov

1

72

134

Daniel J Drucker

@DanielJDrucker

3 months

The latest Ground Truths Podcast @EricTopol The GLP-1 story, from #insulin to #weightloss #obesity #heartdisease #kidney disease #Parkinsons #Alzheimers with a dash of GIP, some glucagon, a bit of neuroscience #inflammation and a look to the future

6

35

130

Daniel J Drucker

@DanielJDrucker

4 years

Saxenda® (liraglutide) @novonordisk injection 3 mg daily becomes the first @US_FDA -approved therapy to treat #obesity in adolescents in more than a decade Updated prescribing label issued in USA

A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity | NEJM

Obesity is a chronic disease with limited treatment options in pediatric patients. Liraglutide may be useful for weight management in adolescents with obesity. In this randomized, double-blind tria...

www.nejm.org

2

22

130

Daniel J Drucker

@DanielJDrucker

2 years

Can one enhance adipose tissue SREBP1c to remove senescent adipocytes and improve metabolic health? #Aging #obesity @Cell_Metabolism

1

44

131